Profile data is unavailable for this security.
About the company
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
- Revenue in USD (TTM)329.75k
- Net income in USD-43.31m
- Incorporated2017
- Employees47.00
- LocationAditxt Inc737 N. Fifth Street, Suite 200RICHMOND 23219United StatesUSA
- Phone+1 (909) 488-0844
- Fax+1 (302) 697-4597
- Websitehttps://aditxt.com/
More ▼
Mergers & acquisitions
| Acquired company | ADTX:NAQ since announced | Transaction value |
|---|---|---|
| Evofem Biosciences Inc | -94.18% | 100.00m |
Data delayed at least 15 minutes, as of Sep 25 2024 15:13 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Herborium Group, Inc. | 340.33k | -318.65k | 545.97k | 2.00 | -- | -- | -- | 1.60 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| International Stem Cell Corp | 8.32m | -529.00k | 552.30k | 29.00 | -- | -- | -- | 0.0664 | -0.0661 | -0.0661 | 1.04 | 0.0355 | 1.46 | 2.54 | 11.31 | 286,965.50 | -12.02 | -29.22 | -84.86 | -73.82 | 58.62 | 59.49 | -8.22 | -21.01 | 0.4785 | -3.94 | 0.9254 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| Capstone Therapeutics Corp | 0.00 | -358.00k | 580.00k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| GlobeStar Therapeutics Corp | 0.00 | -1.98m | 581.46k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
| Yield10 Bioscience Inc | 750.00k | -12.70m | 604.39k | 29.00 | -- | -- | -- | 0.8059 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 613.80k | 131.00 | -- | -- | -- | 0.0652 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 782.38k | 15.00 | -- | 0.0396 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Aditxt Inc | 329.75k | -43.31m | 815.33k | 47.00 | -- | 0.0687 | -- | 2.47 | -77.20 | -77.20 | 0.303 | 3.29 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 899.60k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 957.98k | 51.00 | -- | -- | -- | 0.048 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Genprex Inc | 0.00 | -26.14m | 1.03m | 26.00 | -- | 0.2331 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| LadRx Corp | 0.00 | -2.77m | 1.06m | 2.00 | -- | -- | -- | -- | -5.59 | -5.59 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -113.62 | -58.97 | -653.73 | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
Data as of Sep 25 2024. Currency figures normalised to Aditxt Inc's reporting currency: US Dollar USD
0.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Jun 2024 | 11.33k | 0.57% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.22k | 0.11% |
| Group One Trading LPas of 31 Mar 2024 | 603.00 | 0.03% |
| IFP Advisors, Inc.as of 30 Jun 2024 | 503.00 | 0.03% |
| Natixis Investment Managers International SAas of 31 Mar 2024 | 250.00 | 0.01% |
| UBS Securities LLCas of 31 Mar 2024 | 180.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 37.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 13.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 10.00 | 0.00% |
| UBS Financial Services, Inc.as of 31 Mar 2024 | 5.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
